Quoin Pharma Files 8-K on Financial Results & Operations
Ticker: QNRX · Form: 8-K · Filed: Mar 26, 2026 · CIK: 0001671502
| Field | Detail |
|---|---|
| Company | Quoin Pharmaceuticals, Ltd. (QNRX) |
| Form Type | 8-K |
| Filed Date | Mar 26, 2026 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: earnings, financial-results, 8-K, corporate-filing
TL;DR
**Quoin Pharma just dropped an 8-K on financial results, check Exhibit 99.1 for the details!**
AI Summary
Quoin Pharmaceuticals, Ltd. filed an 8-K on March 26, 2026, reporting under Item 2.02, "Results of Operations and Financial Condition," and Item 9.01, "Financial Statements and Exhibits." This filing indicates the company is likely disclosing recent financial performance or significant operational updates. Investors should pay close attention to the accompanying Exhibit 99.1, which typically contains the press release or detailed financial information, as it will reveal the specifics of these results and could impact the stock's valuation.
Why It Matters
This filing signals that Quoin Pharmaceuticals is releasing important financial or operational news, which could directly influence its stock price and investor sentiment.
Risk Assessment
Risk Level: medium — The risk is medium because the filing itself doesn't disclose the actual results, only that they are being reported, leaving uncertainty about the nature of the news.
Analyst Insight
A smart investor would immediately review Exhibit 99.1 to understand the specific financial results and operational updates reported by Quoin Pharmaceuticals, Ltd. before making any investment decisions.
Key Numbers
- 2026-03-26 — Filing Date (The date the 8-K was filed, indicating the timeliness of the information.)
- Item 2.02 — Results of Operations and Financial Condition (The specific item under which financial performance is being reported.)
- Item 9.01 — Financial Statements and Exhibits (The specific item indicating the inclusion of supporting financial documents.)
- EX-99.1 — Exhibit 99.1 (The document type for the primary exhibit containing the detailed financial information.)
Key Players & Entities
- Quoin Pharmaceuticals, Ltd. (company) — the filer of the 8-K
- 0001671502 (company) — the CIK of Quoin Pharmaceuticals, Ltd.
- 2026-03-26 (date) — the filing and acceptance date of the 8-K
Forward-Looking Statements
- Quoin Pharmaceuticals, Ltd. will release a press release detailing its financial results for the period ending March 26, 2026, within Exhibit 99.1. (Quoin Pharmaceuticals, Ltd.) — high confidence, target: 2026-03-26
- The stock price of Quoin Pharmaceuticals, Ltd. will react to the specific financial results disclosed in Exhibit 99.1. (Quoin Pharmaceuticals, Ltd.) — medium confidence, target: 2026-03-27
FAQ
What specific items did Quoin Pharmaceuticals, Ltd. report on in this 8-K filing?
Quoin Pharmaceuticals, Ltd. reported on Item 2.02, "Results of Operations and Financial Condition," and Item 9.01, "Financial Statements and Exhibits," in this 8-K filing dated March 26, 2026.
What is the significance of Exhibit 99.1 mentioned in the filing?
Exhibit 99.1 (tm269662d1_ex99-1.htm) is significant because it is typically where the detailed press release or financial information related to the "Results of Operations and Financial Condition" (Item 2.02) would be found, providing the specifics of the company's performance.
When was this 8-K filing submitted and accepted by the SEC?
This 8-K filing was submitted and accepted by the SEC on the same date, March 26, 2026, at 09:35:33.
What is the CIK number for Quoin Pharmaceuticals, Ltd.?
The CIK number for Quoin Pharmaceuticals, Ltd. is 0001671502, as stated in the filing details.
What is the primary business address for Quoin Pharmaceuticals, Ltd. as listed in the filing?
The primary business address for Quoin Pharmaceuticals, Ltd. is 23 HATA'AS STREET, KFAR SABA, Israel 44425, with a phone number of 97299741444.
Filing Stats: 544 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2026-03-26 09:35:33
Filing Documents
- tm269662d1_8k.htm (8-K) — 27KB
- tm269662d1_ex99-1.htm (EX-99.1) — 82KB
- 0001104659-26-034951.txt ( ) — 281KB
- qnrx-20260326.xsd (EX-101.SCH) — 3KB
- qnrx-20260326_lab.xml (EX-101.LAB) — 33KB
- qnrx-20260326_pre.xml (EX-101.PRE) — 22KB
- tm269662d1_8k_htm.xml (XML) — 3KB
02 Results of Operations and Financial
Item 2.02 Results of Operations and Financial Condition. On March 26, 2026 Quoin Pharmaceuticals Ltd. (the "Company") announced its fourth quarter and fiscal year 2025 financial results. A copy of the Company's press release is attached as Exhibit 99.1 hereto and incorporated by reference herein. The information set forth and incorporated by reference in this Item 2.02 shall not be deemed to be "filed" with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and the Company does not incorporate it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated March 26, 2026 104 Cover Page Interactive Data file (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Date: March 26, 2026 QUOIN PHARMACEUTICALS LTD. By: /s/ Sally Lawlor Name: Sally Lawlor Title: Chief Financial Officer